Company news

OncoSil Medical Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

R&D Refund - 2018 Financial Year

September 24, 2018

IQVIA appointed EU Market Access and Reimbursement Advisor

August 29, 2018

Preliminary Final Report

August 22, 2018

Appendix 4C & Quarterly Update

July 25, 2018

Response to Price Query

May 31, 2018

Oncosil submits Clinical Study Report to Notified Body

May 13, 2018

Clinical Programme Update

April 4, 2018

Oncosil Medical Share Purchase Plan

March 27, 2018

Successful Completion of Capital Raising

March 22, 2018

Presentation-Surgical Resection Outcomes and Capital Raising

March 20, 2018

Positive Early Study Results Continue

February 27, 2018

Appendix 4D & Half Yearly Report and Accounts

February 21, 2018

First Subject Recruited in the United States

February 7, 2018

Additional Receipt of $0.6m R&D Tax Incentive Refund

January 16, 2018

Appendix 3C - Employee Loan Share Buy Back

January 10, 2018

Progress Update on Global Pancreatic Cancer Clinical Study

December 20, 2017

Positive Early Study Results Presented at EANM Congress

October 22, 2017

R&D Refund

September 24, 2017

Progress update on Global Pancreatic Cancer Clinical Study

September 21, 2017

Appendix 4E - Preliminary Final Report 30 June 2017

August 24, 2017

First UK subject recruited

August 21, 2017

CE Mark & Quarterly Activity Update

July 30, 2017

Second subject recruited at Monash Health Melbourne

May 10, 2017

Appendix 4C and Quarterly update

April 26, 2017

First OncoSil Device Implantation procedure completed

April 25, 2017

Specialised Therapeutics Australia supporting OncoSil study

April 19, 2017

US IRB Approval, MD Anderson Cancer Centre

April 18, 2017

UK Central Ethics Approval

April 4, 2017

First subject recruited

March 27, 2017

Appendix 4D & Half Year Accounts

February 22, 2017

MHRA Approval to commence study in UK

February 12, 2017

Ethics Approval for OncoPac Clinical Study

February 1, 2017

Appendix 4C - Quarterly Cash Flow

January 26, 2017

Pancreatic cancer clinical study update

November 27, 2016

Receipt of $2.3m R & D Tax Incentive Refund

September 26, 2016

Appendix 4E - Preliminary final report 30 June 2016

August 30, 2016

Hot Calibration Run of the OncoSil Device

August 17, 2016

FDA IDE Approval

August 2, 2016

Regulatory Update June 2016

June 30, 2016

OncoSil Medical Appoints Global Sales and Marketing Director

May 17, 2016

Appendix 4C - Quarterly Cashflow

April 27, 2016

Oncosils next generation delivery platform

March 30, 2016

$10 Million Institutional Placement

February 11, 2016

US FDA Investigational Device Exemption submitted

February 10, 2016

$10 Million Institutional Placement

February 2, 2016

← Newer news releases

Decks

The 5 newest of 41 decks. Every deck is listed under its year.